Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Jun 23;37(7):1317-1329.
doi: 10.1093/ndt/gfac040.

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial

EMPA-KIDNEY Collaborative Group
Collaborators
Randomized Controlled Trial

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial

EMPA-KIDNEY Collaborative Group. Nephrol Dial Transplant. .

Abstract

Background: The effects of the sodium-glucose co-transporter 2 inhibitor empagliflozin on renal and cardiovascular disease have not been tested in a dedicated population of people with chronic kidney disease (CKD).

Methods: The EMPA-KIDNEY trial is an international randomized, double-blind, placebo-controlled trial assessing whether empagliflozin 10 mg daily decreases the risk of kidney disease progression or cardiovascular death in people with CKD. People with or without diabetes mellitus (DM) were eligible provided they had an estimated glomerular filtration rate (eGFR) ≥20 but <45 mL/min/1.73 m2 or an eGFR ≥45 but <90 mL/min/1.73 m2 with a urinary albumin:creatinine ratio (uACR) ≥200 mg/g. The trial design is streamlined, as extra work for collaborating sites is kept to a minimum and only essential information is collected.

Results: Between 15 May 2019 and 16 April 2021, 6609 people from eight countries in Europe, North America and East Asia were randomized. The mean age at randomization was 63.8 years [standard deviation (SD) 13.9)], 2192 (33%) were female and 3570 (54%) had no prior history of DM. The mean eGFR was 37.5 mL/min/1.73 m2 (SD 14.8), including 5185 (78%) with an eGFR <45 mL/min/1.73 m2. The median uACR was 412 mg/g) (quartile 1-quartile 3 94-1190), with a uACR <300 mg/g in 3194 (48%). The causes of kidney disease included diabetic kidney disease [n = 2057 (31%)], glomerular disease [n = 1669 (25%)], hypertensive/renovascular disease [n = 1445 (22%)], other [n = 808 (12%)] and unknown causes [n = 630 (10%)].

Conclusions: EMPA-KIDNEY will evaluate the efficacy and safety of empagliflozin in a widely generalizable population of people with CKD at risk of kidney disease progression. Results are anticipated in 2022.

Keywords: CKD, clinical trial; cardiovascular disease; empagliflozin; sodium-glucose co-transporter 2 inhibitor.

PubMed Disclaimer

Figures

None
Graphical abstract
FIGURE 1:
FIGURE 1:
EMPA-KIDNEY key outcomes.
FIGURE 2:
FIGURE 2:
Inclusion and exclusion criteria for entry into the EMPA-KIDNEY trial.
FIGURE 3:
FIGURE 3:
Trial profile—flow of participants through EMPA-KIDNEY trial recruitment.
See this image and copyright information in PMC

References

    1. Fox CS, Matsushita K, Woodward Met al. . Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012; 380: 1662–1673 - PMC - PubMed
    1. Levin A, Agarwal R, Herrington WGet al. . International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney Int 2020; 98: 849–859 - PubMed
    1. Jafar TH, Schmid CH, Landa Met al. . Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73–87 - PubMed
    1. Lewis EJ, Hunsicker LG, Clarke WRet al. . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860 - PubMed
    1. Brenner BM, Cooper ME, de Zeeuw Det al. . Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869 - PubMed

Publication types

MeSH terms

Substances